Trial reportEuropean journal of clinical pharmacology1991
Use of pentoxifylline as an inhibitor of free radical generation in peripheral vascular disease. Results of a double-blind placebo-controlled study.
Trial report in European journal of clinical pharmacology, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Pentoxifylline for intermittent claudication.The Cochrane database of systematic reviews · 2020Pooled it
- Pentoxifylline for intermittent claudication.The Cochrane database of systematic reviews · 2015Pooled it
- Role of pentoxifylline in neonatal hypoxic ischaemic encephalopathy: a systematic review of animal studies.Laboratory animal research · 2024Review
- Looking beyond the ovary for oncofertility care in women: uterine injury as a potential target for fertility-preserving treatments.Journal of assisted reproduction and genetics · 2020Review
- Protection of Pentoxifylline against Testis Injury Induced by Intermittent Hypobaric Hypoxia.Oxidative medicine and cellular longevity · 2016Article
- Review
- A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity.European journal of clinical pharmacology · 2013Review
- Pentoxifylline attenuates ischemia/reperfusion injury to the small intestine in the rat.Pediatric surgery international · 1996Article
- Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders.Drugs & aging · 1995Review
- Tumor necrosis factor-alpha-induced inhibition of phosphatidylcholine synthesis by human type II pneumocytes is partially mediated by prostaglandins.The Journal of clinical investigation · 1994Article
- Pentoxifylline in arterial disease of the legs.European journal of clinical pharmacology · 1991Article
- Review
- Beneficial effect of pentoxifylline into the testis of rats in an experimental model of unilateral hindlimb ischemia/reperfusion injury.International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effects of an infusion of pentoxifylline 1 g as an inhibitor of free radical generation have been determined in a double-blind placebo-controlled study. Leucocyte-derived free radical generation (by the superoxide dismutase-inhibitable reduction of ferricytochrome), the release of reactive oxygen metabolites (as plasma oxidant activity), unfractionated leucocyte and erythrocyte filterability rates (using a constant-flow positive-pressure system), plasma viscosity, and plasma fibrinogen concentration have been measured in two matched groups of 10 patients with Stage II peripheral vascular disease, before and after treatment. Transcutaneous oxygen pressure (PtcO2) during treadmill exercise to stress leg circulation was also measured. Leucocyte-derived free radicals were generated during peripheral ischaemia. Pentoxifylline inhibited their generation, blocked the release of reactive oxygen metabolites, and reduced impairment of the filterability rate of unfractionated leucocytes. The improvements were accompanied by significant shortening of the half-time of recovery of transcutaneous oxygen pressure, indicating that ischaemic damage had been contained.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.